Showing results (371-380 of 583) with videos related to

Sort By:
Pageof 59
Molecular Cancer Therapeutics|July 26, 2015
The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate BiosynthesisShinichi Kiyonari, Makoto Iimori, Kazuaki Matsuoka, et al.
Asian Journal of Endoscopic Surgery|August 18, 2024
Validity of laparoscopic surgery for lower gastrointestinal perforationsKensuke Kudou, Ryoko Aoyama, Kento Ishihara, et al.
Clinical Journal of Gastroenterology|January 9, 2021
Late recurrence of cancer stem cell-positive colorectal cancer liver metastases after 15 yearsTaichi Nagano, Shinji Itoh, Yu Miyashita, et al.
International Cancer Conference Journal|August 14, 2023
A pathological complete response after immunotherapy with pembrolizumab for distal duodenal adenocarcinoma caused by Lynch syndrome: a case reportShinichiro Ikeda, Qingjiang Hu, Keita Natsugoe, et al.
BMC Cancer|June 8, 2021
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancerHiromichi Nakajima, Daisuke Kotani, Hideaki Bando, et al.
The Journal of Medical Investigation : JMI|September 25, 2015
Treatment results of two-stage operation for the patients with esophageal cancer concomitant with liver dysfunctionMitsuhiro Yasuda, Hiroshi Saeki, Yuichiro Nakashima, et al.
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|April 4, 2014
[Patient with bulky duodenum GIST became complete resection possible after primary systemic therapy: a case report]Hajime Otsu, Eiji Oki, Hiroyuki Kawano, et al.
Investigational New Drugs|May 21, 2021
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II studyDaisuke Kotani, Takayuki Yoshino, Masahito Kotaka, et al.
Scientific Reports|September 29, 2021
Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancerQingjiang Hu, Takaaki Masuda, Kensuke Koike, et al.
American Journal of Surgery|July 15, 2018
Postoperative development of sarcopenia is a strong predictor of a poor prognosis in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancerKensuke Kudou, Hiroshi Saeki, Yuichiro Nakashima, et al.
Pageof 59